Terra Reynolds, Global Vice Chair of the Healthcare & Life Sciences Industry Group and Co-Chair of the Chicago Litigation & Trial Department, represents clients in internal and government investigations and complex litigation matters.
Drawing on more than a decade of experience as a former federal prosecutor, Ms. Reynolds regularly advises corporations, boards of directors, and individual executives on their most sensitive matters involving a range of alleged misconduct.
A significant focus of Ms. Reynolds’ work is defending against allegations of healthcare fraud and abuse laws, including the False Claims Act (FCA) and the Anti-Kickback Statute (AKS). She frequently handles high-profile investigations brought by the US Department of Justice (DOJ), the US Department of Health and Human Services Office of Inspector General (HHS OIG), the US Food and Drug Administration (FDA), and the Drug Enforcement Administration (DEA).
Prior to entering private practice, Ms. Reynolds served as an Assistant US Attorney in the Northern District of Illinois, and most recently, as a Deputy Chief. In these roles, she tried more than a dozen federal criminal cases and led numerous investigations. She also briefed and argued matters before the US Court of Appeals for the Seventh Circuit.
Since entering private practice, Ms. Reynolds has handled dozens of matters on behalf of some of the world’s leading healthcare and life sciences companies, as well as individual executives.
Ms. Reynolds is a member of Latham’s Chicago Women Enriching Business Committee (WEB). Outside of the firm, Ms. Reynolds serves as an adjunct professor of trial advocacy at Northwestern University School of Law. She is also a member of the Board of Directors for Legal Aid Chicago.
Ms. Reynolds clerked for US District Judge Marvin E. Aspen of the US District Court for the Northern District of Illinois.
Ms. Reynolds’ experience includes representing:
- A nationwide hospital system and healthcare management company in connection with a series of internal investigations of individual and corporate compliance with policies and federal regulations
- A physician-owned surgical hospital in connection with an internal investigation of compliance with federal regulations
- A medical device company in connection with an internal investigation into a cross-border supply chain issue
- A data analytics company in connection with an internal investigation regarding allegations of financial irregularities and employee misconduct
- A pharmaceutical company in connection with an internal review of its patient support program*
- An international tobacco company in connection with a review of whistleblower allegations regarding the compliance of its sales and marketing practices with FDA regulations
- An international generic manufacturer of opioids in connection with an internal review of its DEA compliance program
- A multinational pharmaceutical company in preparing a crisis management plan*
- A nationwide hospital system in a DOJ FCA investigation, resulting in a declination to intervene and dismissal of the lawsuit
- A nationwide healthcare management company and a physician-owned surgical hospital in the resolution of an FCA matter involving alleged AKS violations
- An ambulatory surgery center (ASC) in a DOJ criminal investigation involving allegations of medical necessity and healthcare fraud
- A nationwide healthcare management company and a physician-owned surgical hospital in the submission of a self-disclosure matter to the HHS-OIG
- A medical waste management company in a DOJ civil investigation of its historic DEA retail pharmacy business
- A former medical device company executive in a DOJ civil healthcare fraud investigation, resulting in a declination
- A medical device sales representative in a DOJ healthcare fraud investigation regarding alleged violations of the FCA and the AKS, resulting in a declination
- A former union executive in a DOJ criminal investigation into alleged embezzlement of union funds
- A private equity-backed provider of rehabilitation management services in the resolution of an FCA lawsuit without the imposition of a Corporate Integrity Agreement (CIA)
- A private equity-backed provider of rehabilitation management services in DOJ healthcare fraud investigations, resulting in declinations to intervene in whistleblower lawsuits
- A multinational pharmaceutical company in connection with a DOJ investigation into its patient support program, drug pricing, and specialty pharmacy issues*
- A domestic pharmaceutical company in connection with FDA and DOJ investigations into its sales and marketing practices*
- A healthcare revenue cycle management company in a non-intervened qui tam lawsuit alleging violations of the FCA and AKS
- A leading provider of radiology imaging services in a civil racketeering and healthcare fraud lawsuit
- An international law firm in a defamation lawsuit, resulting in a dismissal of the complaint that was affirmed on appeal
- An international law firm in a defamation lawsuit, resulting in a dismissal of the complaint
- A wrongfully convicted individual in a civil rights lawsuit against the City of Chicago and individual officers
- A respondent in an International Chamber of Commerce (ICC) arbitration in Singapore concerning allegations of fraud arising from a multibillion-dollar acquisition of an international pharmaceutical company*
- Private equity investors in prospective healthcare transactions
- Buyers, sellers, and underwriters in diligence for transactions, including initial public offerings, involving healthcare and life sciences companies
*Matter handled prior to joining Latham & Watkins